Deep Dive: Deep Dive Into Drug Development Through Pathway Approach

The COVID pandemic is driving interest in the importance of the immune system to human health, and platform technologies to preventing and treating disease. There are roughly 60 million patients in western society dealing with immune mediated diseases. Tackling drug development through a pathway approach opens the potential to treat multiple diseases with one therapy. New ongoing research by Janssen Immunology continues to validate their “pipeline in a pathway” model to treating immune mediated diseases in multiple therapeutic areas including psoriasis, psoriatic arthritis, Crohn’s, ulcerative colitis and more.